dihexa 30mg Capsules Dihexa Peptide Therapy | Memory

The Ghost Trial In the late 1990s and early 2000s, the Croatian pharmaceutical company Pliva sponsored clinical trials for BPC-157 as a treatment for inflammatory bowel disease

Experimental studies have explored potential interactions with multiple signaling systems and regulatory pathways, but no single receptor target has achieved broad consensus

10.1136/gutjnl-2013-304676 62 MearinF.CamilleriM.MalageladaJ

It is contraindicated in certain conditions such as active malignancy and must be used cautiously in those with diabetes, prediabetes, or a history of pituitary disease, which is why careful screening and regular monitoring are essential

That specificity is what makes peptides powerful and also what makes generic protocols a poor fit for most patients